Newsroom | Co-Diagnostics, Inc.

Newsroom

Month Year

Media Resources

Jan 21, 2022

Co-Diagnostics, Inc. to Host Booth at Medlab Middle East 2022 in Dubai on January 24-27

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Jan 13, 2022

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Jan 10, 2022

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 BioConnect Virtual Conference on January 10-13

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Dec 31, 2021

Co-Diagnostics, Inc. Announces Completion of the Acquisition of all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...
Dec 22, 2021

Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...
Dec 7, 2021

Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Nov 29, 2021

Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, reported today that none of...
Nov 15, 2021

Co-Diagnostics, Inc. to Host Booth at MEDICA 2021 Trade Fair in Düsseldorf, Germany

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Nov 11, 2021

Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results

Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the...
Nov 4, 2021

Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom

Company's validated test available in the UK following implementation of UKHSA CTDA Regulations

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2...

Show per page